GlobeNewswire: NovaBay Pharmaceuticals, Inc. Contains the last 10 of 134 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T11:55:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/08/09/1899965/0/en/NovaBay-Pharmaceuticals-Announces-Pricing-of-2-7-Million-Private-Placement-of-Preferred-Stock-and-Accompanying-Warrants-to-Purchase-Common-Stock.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock2019-08-09T13:26:42Z<![CDATA[EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain non-U.S. institutional accredited investors providing for the purchase and sale, in a private placement, of (i) the Company’s preferred stock automatically convertible into 2,700,00 shares of common stock upon approval of the Company’s stockholders, and (ii) accompanying warrants to purchase up to one share of common stock for each share of common stock convertible from the preferred stock, with an exercise price of $1.15 per share, which is expected to result in total gross proceeds of approximately $2.7 million. The warrants will be exercisable upon approval of the Company’s stockholders and will expire five and a half years following the date of issuance. The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2019/08/09/1899962/0/en/NovaBay-Pharmaceuticals-Announces-Pricing-of-4-2-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering2019-08-09T13:22:35Z<![CDATA[EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million. The Company also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to one share of common stock for each share purchased with an exercise price of $1.15 per share. The warrants will be exercisable six months after issuance and will expire five and a half years following the date of issuance. The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2014/11/12/682394/10107539/en/NovaBay-Pharmaceuticals-Reports-Third-Quarter-2014-Financial-Results-and-a-Clinical-Business-Update.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update2014-11-12T12:03:23Z<![CDATA[Q3 Commercial Highlights:]]>https://www.globenewswire.com/news-release/2014/03/20/619914/10073374/en/NovaBay-Pharmaceuticals-Inc-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants2014-03-20T13:00:00Z<![CDATA[EMERYVILLE, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- NovaBay]]>https://www.globenewswire.com/news-release/2014/03/19/619697/10073285/en/NovaBay-Pharmaceuticals-Inc-Announces-Proposed-Public-Offering-of-Common-Stock-and-Warrants.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants2014-03-19T20:32:26Z<![CDATA[EMERYVILLE, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- NovaBay]]>https://www.globenewswire.com/news-release/2014/03/07/616665/10071653/en/NovaBay-Pharmaceuticals-Reports-Fourth-Quarter-2013-and-2013-Year-End-Financial-Results-and-Provides-a-Clinical-Business-Update.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides a Clinical/Business Update2014-03-07T13:30:00Z<![CDATA[
EMERYVILLE, Calif., March 7, 2014 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing non-antibiotic, topical anti-microbial products, today reported fourth quarter 2013 and fiscal year 2013 financial results and provided a clinical and business update.]]>https://www.globenewswire.com/news-release/2014/03/06/616445/10071623/en/NovaBay-CEO-Comments-on-President-Obama-s-Superbug-Budget-Initiative-and-Reports-by-the-CDC-on-Antibiotic-Resistance.html?f=22&fvtc=4&fvtv=10987NovaBay CEO Comments on President Obama's 'Superbug' Budget Initiative and Reports by the CDC on Antibiotic Resistance2014-03-06T20:22:20Z<![CDATA[A recent journal article by NovaBay researchers describes the growing threat of resistance - and how the nation can fight it]]>https://www.globenewswire.com/news-release/2014/02/26/613515/10070104/en/NovaBay-Pharmaceuticals-Grants-Principle-Business-Enterprises-Exclusive-Marketing-and-Distribution-Rights-in-the-US-for-NeutroPhase-R-an-Advanced-Wound-and-Skin-Cleanser.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals Grants Principle Business Enterprises Exclusive Marketing and Distribution Rights in the US for NeutroPhase(R), an Advanced Wound and Skin Cleanser2014-02-26T13:30:00Z<![CDATA[Recent In Vitro Study, Published in a Peer-Reviewed Journal, Demonstrated that NeutroPhase is Best Among Products Tested and Kills Bacteria Quickly]]>https://www.globenewswire.com/news-release/2014/02/17/610814/10068579/en/NovaBay-s-NeutroPhase-R-is-Best-in-Class-in-Laboratory-Study-of-19-Top-Commercial-Wound-Cleansers.html?f=22&fvtc=4&fvtv=10987NovaBay's NeutroPhase(R) is Best in Class in Laboratory Study of 19 Top Commercial Wound Cleansers2014-02-17T14:30:00Z<![CDATA[The In Vitro Study, Published in the Peer-Reviewed Journal Advances in Skin & Wound Care, Showed that NeutroPhase Kills Bacteria Quickly]]>https://www.globenewswire.com/news-release/2014/02/07/608488/10067468/en/NovaBay-Pharmaceuticals-to-Present-at-the-Annual-Dialysis-Conference-in-Atlanta.html?f=22&fvtc=4&fvtv=10987NovaBay Pharmaceuticals to Present at the Annual Dialysis Conference in Atlanta2014-02-07T13:30:00Z<![CDATA[Nephrologist Allan Kavalich, MD, to Discuss Improvements in Infections Associated With Peritoneal Dialysis Catheters With Use of NeutroPhase - Pure 0.01% Hypochlorous Acid Solution]]>